CR20230538A - Compuestos y métodos dirigidos a la epirregulina - Google Patents

Compuestos y métodos dirigidos a la epirregulina

Info

Publication number
CR20230538A
CR20230538A CR20230538A CR20230538A CR20230538A CR 20230538 A CR20230538 A CR 20230538A CR 20230538 A CR20230538 A CR 20230538A CR 20230538 A CR20230538 A CR 20230538A CR 20230538 A CR20230538 A CR 20230538A
Authority
CR
Costa Rica
Prior art keywords
epiregulin
chronic
compounds
pain
methods targeting
Prior art date
Application number
CR20230538A
Other languages
English (en)
Inventor
Jeffrey Streetman Boyles
Michael Parvin Johnson
Catherine Brautigam Beidler
Daniel Scott Girard
Shannon Marie Harlan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230538A publication Critical patent/CR20230538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con anticuerpos de la epirregulina, composiciones que los comprenden, y métodos para elaborar y/o usar los anticuerpos y/o composiciones de estos para trastornos del dolor crónico tales como el dolor de la osteoartritis crónico, o el dolor de la neuropatía periférica diabética crónico, o el dolor lumbar crónico.
CR20230538A 2021-05-21 2022-05-19 Compuestos y métodos dirigidos a la epirregulina CR20230538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191496P 2021-05-21 2021-05-21
PCT/US2022/030058 WO2022246078A1 (en) 2021-05-21 2022-05-19 Compounds and methods targeting epiregulin

Publications (1)

Publication Number Publication Date
CR20230538A true CR20230538A (es) 2023-12-11

Family

ID=82100776

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230538A CR20230538A (es) 2021-05-21 2022-05-19 Compuestos y métodos dirigidos a la epirregulina

Country Status (20)

Country Link
US (2) US12600767B2 (es)
EP (1) EP4341288A1 (es)
JP (2) JP7696449B2 (es)
KR (1) KR20240009488A (es)
CN (1) CN117440968A (es)
AR (1) AR125902A1 (es)
AU (1) AU2022277694A1 (es)
BR (1) BR112023021829A2 (es)
CA (1) CA3218753A1 (es)
CL (1) CL2023003404A1 (es)
CO (1) CO2023015694A2 (es)
CR (1) CR20230538A (es)
DO (1) DOP2023000253A (es)
EC (1) ECSP23087684A (es)
IL (1) IL308533A (es)
JO (1) JOP20230295A1 (es)
MX (1) MX2023013718A (es)
PE (1) PE20240416A1 (es)
TW (1) TWI859538B (es)
WO (1) WO2022246078A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
RU2312109C2 (ru) 2003-03-14 2007-12-10 Тайсо Фармасьютикал Ко., Лтд. Моноклональное антитело и продуцирующая его гибридома
CN100512806C (zh) 2003-04-14 2009-07-15 Lts勒曼治疗系统股份公司 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂
AU2005232657B2 (en) * 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA2891855A1 (en) * 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
MX2015017852A (es) 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
EP3978525A1 (en) 2015-06-29 2022-04-06 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
JP2019202936A (ja) 2016-08-17 2019-11-28 中外製薬株式会社 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬
TWI807338B (zh) 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途

Also Published As

Publication number Publication date
AU2022277694A1 (en) 2023-11-30
DOP2023000253A (es) 2023-12-29
IL308533A (en) 2024-01-01
AU2022277694A9 (en) 2023-12-07
US20250101091A1 (en) 2025-03-27
PE20240416A1 (es) 2024-03-05
CN117440968A (zh) 2024-01-23
EP4341288A1 (en) 2024-03-27
JP2025134758A (ja) 2025-09-17
KR20240009488A (ko) 2024-01-22
JOP20230295A1 (ar) 2023-11-19
CA3218753A1 (en) 2022-11-24
ECSP23087684A (es) 2023-12-29
WO2022246078A1 (en) 2022-11-24
US12600767B2 (en) 2026-04-14
JP2024522071A (ja) 2024-06-11
MX2023013718A (es) 2024-01-16
JP7696449B2 (ja) 2025-06-20
BR112023021829A2 (pt) 2023-12-19
TW202313680A (zh) 2023-04-01
CO2023015694A2 (es) 2023-11-30
TWI859538B (zh) 2024-10-21
AR125902A1 (es) 2023-08-23
CL2023003404A1 (es) 2024-06-21
US20220372124A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
PH12021551487A1 (en) Tumor-targeted agonistic cd28 antigen binding molecules
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
NZ754051A (en) Novel antibodies and uses thereof
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
PH12022553167A1 (en) Agonistic cd28 antigen binding molecules targeting her2
WO2019147749A3 (en) Stabilized rsv f proteins and uses thereof
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
PH12012501761A1 (en) Anti-nerve growth factor (ngf) antibody compositions
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
EA201071300A1 (ru) Антитела к cxcr4
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
WO2020132378A3 (en) Compositions and methods of treatment for neurological disorders comprising depression
WO2019118512A3 (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
ZA202110285B (en) Antibodies and methods of use
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
ZA202006216B (en) Antibodies targeting glycoprotein vi
EA202193040A1 (ru) Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения
CR20230538A (es) Compuestos y métodos dirigidos a la epirregulina